MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory illnesses. Most of us are familiar with the usual winter players such as ...

In recent years, the human metapneumovirus hMPV therapeutics market size saw substantial growth. From 2024 to 2025, it is projected to grow from $0.66 billion to $0.70 billion, reflecting a ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...

Human metapneumovirus (HMPV ... Until now, no specific vaccination or antiviral treatment exists for HMPV. Preventive measures like washing hands, avoiding contact with infected individuals ...

Human metapneumovirus (HMPV ... Currently, there is no specific antiviral treatment or vaccine for HMPV; management focuses on relieving symptoms. Also Read: Young blood for 2028 U.S elections?

Human metapneumovirus (hMPV), a respiratory pathogen identified in 2001, is a substantial cause of community-acquired respiratory infections across all age groups. This Review explores the impact of ...

An Auckland high school closed early today after sickness left it unable to staff all classes, and as a top GP warns that the ...

Tracking measles through wastewater is giving health officials a new window into where the virus is spreading.